comparemela.com

Stephenb Hanauer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biosimilars Month in Review: May 2024

The biosimilars month in review highlights recent FDA approvals and successful comparison trials.

United kingdomClare harrisAdalimumab biosimilarsBoehringer ingelheimStephenb hanauerStephen pagnottaDivision of gastroenterologyNorthwestern universityFeinberg school of medicineDrug administrationDepartment of medicineUniversity of southamptonExecutive directorBiosimilar commercial leadFeinberg school

Infliximab Biosimilar CT-P13 Superior to Placebo for IBD Maintenance

Statistically significant higher proportions of patients with CD or UC receiving subcutaneous CT-P13 achieved clinical remission compared with placebo.

Stephenb hanauerDrug administrationEuropean medicines agencyNorthwestern medicineDisease activity index

Q&A: Zymfentra gives patients an option for at-home maintenance therapy of IBD

Q&A: Zymfentra gives patients an option for at-home maintenance therapy of IBD
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Remicade janssenStephenb hanauerZymfentra celltrionTakeda pharmaceuticalsClifford joseph barborka professorNorthwestern university feinberg school

Biosimilars as Effective as Originator Biologics in IBD

In a systematic review, outcomes such as remission and loss of response were similar between patients with IBD who continued their original biologic and those who switched to a biosimilar.

United kingdomBritish columbiaUnited statesJohn marshallStephenb hanauerSusanna meadeNorthwestern university feinberg school of medicineHealth canadaJournal of the canadian association gastroenterologyCanadian association of gastroenterologyUniversity of british columbiaMcmaster universityCanadian associationColitis canadaNew brunswickNorthwestern university feinberg school

Data Presented at UEG Week 2023 Further Support the Potential of Celltrion s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease

The latest clinical trial data for subcutaneous (SC) infliximab (CT-P13 SC), presented at the United European Gastroenterology (UEG) Week 2023 in Copenhagen, further support the potential of CT-P13 SC in patients with inflammatory bowel disease (IBD).LIBERTY-CD and LIBERTY-UC are registrational studies in patients w.

United statesNew jerseyStephenb hanauerTom nusbickelCelltrion incDrug administrationEuropean commissionDigestive health center at northwestern medicineEuropean medicines agencyFeinberg school of medicineUnited european gastroenterologyCelltrion healthcareBiologics license applicationDigestive health centerNorthwestern medicineFeinberg school

vimarsana © 2020. All Rights Reserved.